Brief: Targovax Announces Collaborative Agreement With Merck & Co

Circio Holding ASA

23/06/2020 06:10

June 23 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN
COMBINATION WITH KEYTRUDA ®  IN MESOTHELIOMA
    * COLLABORATIVE AGREEMENT WITH MERCK & CO., INC.,
KENILWORTH, NJ,
USA
    * AIM IS TO START ENROLLING PATIENTS INTO TRIAL WITHIN
TWELVE
MONTHS
    * MULTIPLE CENTERS IN BOTH USA AND EU WILL BE PARTICIPATING
    * TO EVALUATE COMBINATION OF ONCOS-102, KEYTRUDA MSD'S
ANTI-PD-1
THERAPY, AND STANDARD OF CARE CHEMOTHERAPY IN MALIGNANT PLEURAL
MESOTHELIOMA
    * TRIAL WILL BE A RANDOMIZED PHASE II OF UP TO 100 PATIENTS
COMPARING THIS INVESTIGATIONAL TRIPLE COMBINATION AGAINST
KEYTRUDA AND SOC

Source text for Eikon:  ID:nWkr47LFMn 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))